Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Explore

Analyst Notes

Stocks – Q : Quality | V : Valuation | PT : Price Trend
Funds – P : Performance | Q : Quality

Top Pharma Companies in India by Market Cap

BSE Sensex 77328.19
516.33 (-0.66%)

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Lincoln Pharmaceuticals Ltd.	Q V PT	1,354 Small Cap	676 (0.83%)	15.29	1.8	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Sai Life Sciences Ltd.	Q V+ PT	23,680 Small Cap	1,116.85 (2.55%)	70.21	9.62	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Divis Laboratories Ltd.	Q V+ PT	1,78,100 Large Cap	6,708.90 (0.12%)	71.76	11.12	11.65	10.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Alkem Laboratories Ltd.	Q V+ PT	66,679 Mid Cap	5,576.80 (-0.25%)	30.47	4.68	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Emcure Pharmaceuticals Ltd.	Q V PT	31,123 Small Cap	1,641.60 (-1.28%)	43.01	8.5	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Themis Medicare Ltd.	Q V PT	902 Small Cap	97.96 (-0.86%)	N/A	3.04	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Sigachi Industries Ltd.	Q V+ PT	841 Small Cap	22.01 (4.96%)	N/A	1.7	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Gland Pharma Ltd.	Q V PT	31,377 Small Cap	1,904.45 (1.78%)	26.37	2.98	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Alivus Life Sciences Ltd.	Q V+ PT	13,758 Small Cap	1,120.90 (-0.03%)	25.31	4.35	9.20	6.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Pfizer Ltd.	Q V PT	22,009 Small Cap	4,811.05 (1.29%)	25.46	5.45	1.18	5.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Ipca Laboratories Ltd.	Q V+ PT	39,369 Mid Cap	1,551.75 (-0.39%)	49.09	5.13	8.87	4.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	Syngene International Ltd.	Q V+ PT	18,488 Small Cap	458 (-2.43%)	62.15	4.03	10.89	4.48	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	Aarti Drugs Ltd.	Q V+ PT	3,545 Small Cap	388.45 (-2.34%)	17.92	2.41	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Laurus Labs Ltd.	Q V+ PT	66,373 Mid Cap	1,229.45 (1.91%)	73.28	12.29	14.42	4.11	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Eris Lifesciences Ltd.	Q V PT	19,212 Small Cap	1,386.75 (0.22%)	44.4	5.29	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Bajaj Healthcare Ltd.	Q V PT	1,134 Small Cap	336.90 (-0.88%)	21.87	2	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Metropolis Healthcare Ltd.	Q V PT	11,409 Small Cap	550.30 (8.83%)	62.31	6.96	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	FDC Ltd.	Q V PT	6,196 Small Cap	380.55 (1.36%)	26.92	2.48	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Fermenta Biotech Ltd.	Q V PT	850 Small Cap	288.70 (-4.07%)	12.3	2.14	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	Hester Biosciences Ltd.	Q V+ PT	1,403 Small Cap	1,649.65 (0.70%)	39.42	3.89	11.08	0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	Aster DM Healthcare Ltd.	Q V+ PT	38,465 Small Cap	742.40 (0.57%)	98.54	8.36	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Laxmi Dental Ltd.	Q V PT	1,181 Small Cap	214.95 (-1.20%)	92.67	5.04	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Suven Life Sciences Ltd.	Q V+ PT	5,911 Small Cap	224.15 (1.56%)	N/A	3.78	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	2,847 Small Cap	96.98 (-0.92%)	24.79	1.62	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Wockhardt Ltd.	Q V+ PT	26,111 Small Cap	1,606.90 (-1.82%)	124.86	5.38	1.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	CORONA Remedies Ltd.	Q V+ PT	10,472 Small Cap	1,712.15 (-1.50%)	71.33	15.18	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Orchid Pharma Ltd.	Q V PT	3,571 Small Cap	704.10 (3.33%)	81.41	2.58	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	Park Medi World Ltd.	Q V PT	10,779 Small Cap	249.55 (1.40%)	1480.68	11.83	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Krsnaa Diagnostics Ltd.	Q V PT	1,949 Small Cap	600.95 (-0.67%)	24.41	2.09	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Senores Pharmaceuticals Ltd.	Q V+ PT	4,451 Small Cap	966.55 (3.66%)	311.4	5.99	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Company Name	CMP	Price Change(%)
Metropolis Health.	550.30	8.83%
Shree Ganesh Remed.	530.60	8.65%
KMC Speciality Hosp	95.47	6.85%
Guj. Kidney & Super	139.85	6.84%
Nectar Lifesciences	14.39	5.89%

Company Name	CMP	Price Change(%)
Indoco Remedies	228.20	-9.17%
Windlas Biotech	820.55	-4.24%
Panacea Biotec	388.15	-4.16%
Fermenta Biotech	288.70	-4.07%
Lupin	2,377.90	-3.33%

News about Top Pharma Companies in India

May, 2026

USFDA completes inspection at Alkem Laboratories’ CRO facility in Taloja

At the end of the inspection, no form 483 was issued

May, 2026

Emcure Pharmaceuticals informs about ESG rating

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A Para A of Schedule III and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Emcure Pharmaceuticals has informed that NSE Sustainability Ratings & Analytics, a SEBI registered Environmental, Social, and Governance (ESG) Rating Provider, has voluntarily and independently assigned ESG rating of 21 to the Company, for the Financial Year 2024-25, based on information available in public domain. This disclosure is being made based on the information received by the Company vide email dated May 07, 2026, about such rating.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Laurus Labs informs about newspaper advertisements

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed copies of the newspaper advertisements pertaining to Notice to Shareholders with respect to, ‘Submission of TDS related documents for 2nd Interim Dividend for FY 2025-26’. The advertisements were published in ‘Business Standard’ (English) and ‘Prajasakti’ (Telugu) on May 07, 2026.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Emcure Pharma - Quaterly Results

A fair growth of 14.83% in the revenue at Rs. 14677.03 millions was reported in the March 2026 quarter as compared to Rs. 12781.88 millions during year-ago period.Net profit surges 67.46% to Rs. 2336.97 millions from Rs. 1395.57 millions in the quarter ended March 2026.The company reported a good operating profit of 3985.94 millions compared to 2670.33 millions of corresponding previous quarter.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	14677.03	12781.88	14.83	52431.88	43819.24	19.65	52431.88	43819.24	19.65
Other Income	269.39	223.96	20.28	2095.16	1188.07	76.35	2095.16	1188.07	76.35
PBIDT	3985.94	2670.33	49.27	13342.66	7656.44	74.27	13342.66	7656.44	74.27
Interest	368.67	240.69	53.17	1182.71	1129.62	4.70	1182.71	1129.62	4.70
PBDT	3693.06	2429.64	52.00	11909.24	6526.82	82.47	11909.24	6526.82	82.47
Depreciation	630.40	569.12	10.77	2467.33	2249.72	9.67	2467.33	2249.72	9.67
PBT	3062.66	1860.52	64.61	9441.91	4277.10	120.75	9441.91	4277.10	120.75
TAX	725.69	464.95	56.08	2112.32	1105.82	91.02	2112.32	1105.82	91.02
Deferred Tax	-62.93	-170.95	-63.19	-225.09	-21.25	959.25	-225.09	-21.25	959.25
PAT	2336.97	1395.57	67.46	7329.59	3171.28	131.12	7329.59	3171.28	131.12
Equity	1895.90	1894.83	0.06	1895.90	1894.83	0.06	1895.90	1894.83	0.06
PBIDTM(%)	27.16	20.89	29.99	25.45	17.47	45.64	25.45	17.47	45.64

May, 2026

Emcure Pharmaceuticals informs about change in management

Pursuant to Regulation 30 of the SEBI Listing Regulations and based on the recommendation of the Nomination and Remuneration Committee, Emcure Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held today i.e. Tuesday, May 05, 2026, has approved the re-appointment of the following Directors, subject to approval of shareholders: 1. Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company for a further period of 1 (One) year commencing from August 28, 2026; 2. Satish Mehta (DIN: 00118691) as the Managing Director of the Company, for a further period of 5 (Five) years with effective from April 01, 2027. Dr. Mukund Gurjar and Satish Mehta are not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India (‘SEBI’) SEBI order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and that they are not related to any Director(s) or Key Managerial Personnel(s) of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed. The meeting of the Board of Directors of the Company commenced at 12.42 pm (IST) and concluded at 2.00 pm (IST).

The above information is a part of company’s filings submitted to BSE.

May, 2026

Wockhardt - Quaterly Results

A decent increase of about 45.35% in the sales to Rs. 5160.00 millions was observed for the quarter ended March 2026. The sales figure stood at Rs. 3550.00 millions during the year-ago period.Net Profit for the quarter ended March 2026 zoomed to 317.50% from Rs. 400.00 millions to Rs. 1670.00 millions.The company reported a good operating profit of 2160.00 millions compared to 1200.00 millions of corresponding previous quarter.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	5160.00	3550.00	45.35	17390.00	14020.00	24.04	17390.00	14020.00	24.04
Other Income	550.00	140.00	292.86	1370.00	550.00	149.09	1370.00	550.00	149.09
PBIDT	2160.00	1200.00	80.00	6540.00	3550.00	84.23	6540.00	3550.00	84.23
Interest	410.00	400.00	2.50	1760.00	1990.00	-11.56	1760.00	1990.00	-11.56
PBDT	2100.00	800.00	162.50	5030.00	1560.00	222.44	5030.00	1560.00	222.44
Depreciation	430.00	400.00	7.50	1860.00	1680.00	10.71	1860.00	1680.00	10.71
PBT	1670.00	400.00	317.50	3170.00	-120.00	-2741.67	3170.00	-120.00	-2741.67
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	1670.00	400.00	317.50	3170.00	-120.00	-2741.67	3170.00	-120.00	-2741.67
Equity	810.00	810.00	0.00	810.00	810.00	0.00	810.00	810.00	0.00
PBIDTM(%)	41.86	33.80	23.84	37.61	25.32	48.52	37.61	25.32	48.52

Rank	Company	Market Capitalization 2026 (INR crores)
1	Yatharth Hospital & Trauma Care Services Ltd.	8,312 Crore
2	3B Blackbio Dx Ltd.	1,111 Crore
3	Neuland Laboratories Ltd.	22,701 Crore
4	Vimta Labs Ltd.	2,289 Crore
5	Max Healthcare Institute Ltd.	98,526 Crore
6	Novartis India Ltd.	2,747 Crore
7	Narayana Hrudayalaya Ltd.	37,189 Crore
8	Anthem Biosciences Ltd.	44,069 Crore
9	Jagsonpal Pharmaceuticals Ltd.	1,463 Crore
10	Kwality Pharmaceuticals Ltd.	1,817 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,661	56,654	37.17	12.91	26.02	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	65.25	16.32	36.87	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	24.45
Lupin Ltd. (M)	Somewhat Good	2,378	1,08,721	20.39	4.84	11.79	20.83
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	110
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,364	66,722	67.00
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	40.02
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	37.62
Gland Pharma Ltd. (S)	Very Good	1,904	31,377	34.73
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	17.81
Mankind Pharma Ltd. (M)	Very Good	2,427	1,00,200	58.82	6.28	35.25	14.65
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	74.68	12.52	37.46	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	30.57
Cipla Ltd. (L)	Very Good	1,348	1,08,865	23.95	3.24	14.44	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,847	4,43,229	40.61	5.46	22.21	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	19.45

About MoneyWorks4Me

*Color code for outperformance consistency

*Number is average 3 year rolling returns

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

USFDA completes inspection at Alkem Laboratories’ CRO facility in Taloja

Emcure Pharmaceuticals informs about ESG rating

Laurus Labs informs about newspaper advertisements

Emcure Pharma - Quaterly Results

Emcure Pharmaceuticals informs about change in management

Wockhardt - Quaterly Results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

USFDA completes inspection at Alkem Laboratories’ CRO facility in Taloja

Emcure Pharmaceuticals informs about ESG rating

Laurus Labs informs about newspaper advertisements

Emcure Pharma - Quaterly Results

Emcure Pharmaceuticals informs about change in management

Wockhardt - Quaterly Results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.